← Back
How Giving A Voice To The Disenfranchised Improves Public Health For All
July 2022 -- Since prescription drugs are taken by more than 45% of African-American persons, 37% of Hispanic persons and 33% of Asian persons, it behooves the pharmaceutical industry to accommodate their distinct needs throughout the drug development process. The Center for Information and Study on Clinical Research Participation (CISCRP) has confirmed the disproportionate representation of underserved American communities in clinical trials, compelling the FDA to broaden eligibility criteria to better reflect real-world patient demographics and ensure their systematic inclusion.